Structured evidence table for Phytosterols LDL Cholesterol Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Phytosterols LDL Cholesterol Randomized Trial | In rats, phytosterol treatment altered gut microbial composition and the relative abundance of putative bile salt hydrolase (BSH)-producing taxa, accompanied by reduced ileal luminal BSH activity. | 4 | Xia J (2026) | Phytosterol-induced modulation of gut microbial bile salt hydrolases ameliorates hyperlipidemia via taurohyodeoxycholic acid-mediated FXR antagonism. |
| Phytosterols LDL Cholesterol Randomized Trial | These changes coincided with bile acid remodeling, including increased concentrations of taurohyodeoxycholic acid (THDCA) in liver tissue and ileal contents. | 4 | Xia J (2026) | Phytosterol-induced modulation of gut microbial bile salt hydrolases ameliorates hyperlipidemia via taurohyodeoxycholic acid-mediated FXR antagonism. |
| Phytosterols LDL Cholesterol Randomized Trial | Collectively, these findings suggest that dietary phytosterols may ameliorate dyslipidemia partly through modulation of the gut microbiota-bile acid-FXR axis, with microbiota-associated BSH-THDCA-FXR signaling representing one plausible contributing pathway. | 4 | Xia J (2026) | Phytosterol-induced modulation of gut microbial bile salt hydrolases ameliorates hyperlipidemia via taurohyodeoxycholic acid-mediated FXR antagonism. |
| Phytosterols LDL Cholesterol Randomized Trial | Although dietary phytosterols have established lipid-lowering effects, their interactions with the gut-liver metabolic axis remain incompletely understood. | 4 | Xia J (2026) | Phytosterol-induced modulation of gut microbial bile salt hydrolases ameliorates hyperlipidemia via taurohyodeoxycholic acid-mediated FXR antagonism. |
| Phytosterols LDL Cholesterol Randomized Trial | This review synthesizes mechanistic and clinical evidence on non-pharmacological strategies that modulate these pathways and contribute to ASCVD risk reduction. | 4 | Kovyanova TI (2026) | Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration. |
| Phytosterols LDL Cholesterol Randomized Trial | Modulation of the gut microbiome, particularly through increased short-chain fatty acid production and reduced TMAO formation, provides additional cardiometabolic benefits. | 4 | Kovyanova TI (2026) | Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration. |
| Phytosterols LDL Cholesterol Randomized Trial | When combined with evidence-based pharmacotherapy, these interventions exert synergistic effects on cardiometabolic risk factors. | 4 | Kovyanova TI (2026) | Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration. |
| Phytosterols LDL Cholesterol Randomized Trial | Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, driven by complex interactions among dyslipidemia, chronic inflammation, insulin resistance, endothelial dysfunction, and gut microbiome-derived metabolites. | 4 | Kovyanova TI (2026) | Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration. |
Source documents